|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
| ||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||
|
J Am Coll Cardiol, 2007; 49:554-561, doi:10.1016/j.jacc.2006.07.072
(Published online 19 January 2007). © 2007 by the American College of Cardiology Foundation |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,1,*
* Hospital Pedro Hispano, Matosinhos, Portugal
Hospital Clinico Universitário S. Carlos, Madrid, Spain
Oporto University Medical School, Oporto, Portugal
Northwestern University Feinberg School of Medicine, Chicago, Illinois
Manuscript received April 19, 2006; revised manuscript received July 20, 2006, accepted July 23, 2006.
* Reprint requests and correspondence: Dr. Nalini M. Rajamannan, Northwestern University Feinberg School of Medicine, Department of Medicine, Cardiology, 303 E Chicago, Tarry 12-717, Chicago, Illinois 60611. (Email: n-rajamannan{at}northwestern.edu).
OBJECTIVES: The objective of this study was to test the effect of a 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitor on the progression of moderate to severe aortic stenosis as measured by echocardiography.
BACKGROUND: Recent retrospective studies support the hypothesis that statins slow the progression of aortic stenosis.
METHODS: We performed an open-label, prospective study evaluating 121 consecutive patients with asymptomatic moderate to severe aortic stenosis (aortic valve area 
1.0 cm2; mean age 73.7 ± 8.9 years; 57 men and 64 women), treated with and without rosuvastatin according to the National Cholesterol Education Program Adult Treatment Panel III guidelines. Echocardiographic, serum lipid, and inflammatory markers were measured at baseline and every 6 months for 18 months.
RESULTS: Sixty-one patients (50.4%) with elevated LDL (159.7 ± 33.4 mg/dl), aortic valve velocity (3.65 ± 0.64 m/s), and aortic valve area (1.23 ± 0.42 cm2) received rosuvastatin (20 mg/day), and 60 (49.6%) with a normal LDL (118.6 ± 37.4 mg/dl), aortic valve velocity (3.62 ± 0.61 m/s), and aortic valve area (1.20 ± 0.35 cm2) received no statin. During a mean follow-up of 73 ± 24 weeks, the change in aortic valve area in the control group was –0.10 ± 0.09 cm2/year versus –0.05 ± 0.12 cm2/year in the rosuvastatin group (p = 0.041). The increase in aortic valve velocity was 0.24 ± 0.30 m/s/year in the control group and 0.04 ± 0.38 m/s/year in the rosuvastatin group (p = 0.007). There was significant improvement in serum lipid and echocardiographic measures of aortic stenosis in the statin group.
CONCLUSIONS: Prospective treatment of aortic stenosis with rosuvastatin by targeting serum LDL slowed the hemodynamic progression of aortic stenosis. This is the first prospective study that shows a positive effect of statin therapy for this disease process. (Rosuvastatin Affecting Aortic Valve Endothelium; http://www.clinicaltrials.gov/ct/show/NCT00114491?order = 1; NCT0014491).
| |||||||
Related Article
This article has been cited by other articles:
|
|
 |
|
  J. D. Miller, Y. Chu, R. M. Brooks, W. E. Richenbacher, R. Pena-Silva, and D. D. Heistad Dysregulation of Antioxidant Mechanisms Contributes to Increased Oxidative Stress in Calcific Aortic Valvular Stenosis in Humans J. Am. Coll. Cardiol., September 2, 2008; 52(10): 843 - 850. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. M Rajamannan Low-density lipoprotein and aortic stenosis Heart, September 1, 2008; 94(9): 1111 - 1112. [Full Text] [PDF]
|
|
|
|
|
|
C Cote, P Pibarot, J-P Despres, D Mohty, A Cartier, B J Arsenault, C Couture, and P Mathieu Association between circulating oxidised low-density lipoprotein and fibrocalcific remodelling of the aortic valve in aortic stenosis Heart, September 1, 2008; 94(9): 1175 - 1180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. Carabello Aortic Stenosis: It Is a Hot Topic: The Link to Coronary Artery Disease J. Am. Coll. Cardiol., August 26, 2008; 52(9): 764 - 766. [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Greve and K. Wachtell Review: Does lowering cholesterol have an impact on the progression of aortic stenosis? Therapeutic Advances in Cardiovascular Disease, August 1, 2008; 2(4): 277 - 286. [Abstract] [PDF]
|
|
|
|
 |
|
 C. E. Tourmousoglou, S. Lalos, and T. Psarros Do statins slow the progression of aortic valve stenosis? Interactive CardioVascular and Thoracic Surgery, August 1, 2008; 7(4): 684 - 689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Shuvy, S. Abedat, R. Beeri, H. D. Danenberg, D. Planer, I. Z. Ben-Dov, K. Meir, J. Sosna, and C. Lotan Uraemic hyperparathyroidism causes a reversible inflammatory process of aortic valve calcification in rats Cardiovasc Res, August 1, 2008; 79(3): 492 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. M. Rajamannan Update on the pathophysiology of aortic stenosis Eur. Heart J. Suppl., July 1, 2008; 10(suppl_E): E4 - E10. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. R. Pedersen Overview of clinical trials on calcific aortic stenosis Eur. Heart J. Suppl., July 1, 2008; 10(suppl_E): E31 - E40. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Owens, R. Katz, E. Johnson, D. M. Shavelle, J. L. Probstfield, J. Takasu, J. R. Crouse, J. J. Carr, R. Kronmal, M. J. Budoff, et al. Interaction of Age With Lipoproteins as Predictors of Aortic Valve Calcification in the Multi-Ethnic Study of Atherosclerosis Arch Intern Med, June 9, 2008; 168(11): 1200 - 1207. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Demer and Y. Tintut Vascular Calcification: Pathobiology of a Multifaceted Disease Circulation, June 3, 2008; 117(22): 2938 - 2948. [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Jassal, J. W. Tam, K. M. Bhagirath, I. Gaboury, R. A. Sochowski, J. G. Dumesnil, P. J. Giannoccaro, J. Jue, A. S. Pandey, C. D. Joyner, et al. Association of mitral annular calcification and aortic valve morphology: a substudy of the aortic stenosis progression observation measuring effects of rosuvastatin (ASTRONOMER) study Eur. Heart J., June 2, 2008; 29(12): 1542 - 1547. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Pachon and J. Zamorano Mitral annular calcifications and aortic valve stenosis Eur. Heart J., June 2, 2008; 29(12): 1478 - 1480. [Full Text] [PDF]
|
|
|
|
|
|
I G Burwash, S H Little, and K L Chan The authors' reply Heart, April 1, 2008; 94(4): 508 - 508. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Ramaraj and V. L Sorrell Degenerative aortic stenosis BMJ, March 8, 2008; 336(7643): 550 - 555. [Full Text] [PDF]
|
|
|
|
 |
|
 P. De Mozzi, U. G. Longo, G. Galanti, and N. Maffulli Bicuspid aortic valve: a literature review and its impact on sport activity Br. Med. Bull., March 1, 2008; 85(1): 63 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Rahimtoola The Year in Valvular Heart Disease. J. Am. Coll. Cardiol., February 19, 2008; 51(7): 760 - 770. [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Towler Vascular Calcification: A Perspective On An Imminent Disease Epidemic IBMS BoneKEy, February 1, 2008; 5(2): 41 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, P. Clopton, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, J. D. Knoke, W. Y.W. Lew, J. A.C. Lima, et al. Highlights of the year in JACC 2007. J. Am. Coll. Cardiol., January 29, 2008; 51(4): 490 - 512. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Goland, A. Trento, L. S.C. Czer, S. Eshaghian, K. Tolstrup, T. Z. Naqvi, M. A. De Robertis, J. Mirocha, K. Iida, and R. J. Siegel Thoracic Aortic Arteriosclerosis in Patients With Degenerative Aortic Stenosis With and Without Coexisting Coronary Artery Disease Ann. Thorac. Surg., January 1, 2008; 85(1): 113 - 119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Mohty, P. Pibarot, J.-P. Despres, C. Cote, B. Arsenault, A. Cartier, P. Cosnay, C. Couture, and P. Mathieu Association Between Plasma LDL Particle Size, Valvular Accumulation of Oxidized LDL, and Inflammation in Patients With Aortic Stenosis Arterioscler. Thromb. Vasc. Biol., January 1, 2008; 28(1): 187 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. H. Stone C-Reactive Protein to Identify Early Risk for Development of Calcific Aortic Stenosis: Right Marker? Wrong Time? J. Am. Coll. Cardiol., November 13, 2007; 50(20): 1999 - 2001. [Full Text] [PDF]
|
|
|
|
|
|
K.J. Grande-Allen, N. Osman, M.L. Ballinger, H. Dadlani, S. Marasco, and P.J. Little Glycosaminoglycan synthesis and structure as targets for the prevention of calcific aortic valve disease Cardiovasc Res, October 1, 2007; 76(1): 19 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Goldbarg, S. Elmariah, M. A. Miller, and V. Fuster Insights Into Degenerative Aortic Valve Disease J. Am. Coll. Cardiol., September 25, 2007; 50(13): 1205 - 1213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Tuzcu, R. C. Starling, and J. D. Thomas Highlights of the 56th Annual Scientific Session of the American College of Cardiology, March 24-27, 2007. ACC.07 and i2 Summit Highlights: A Conversation With the Experts. J. Am. Coll. Cardiol., August 21, 2007; 50(8 Suppl): C2 - 31. [Full Text] [PDF]
|
|
|
|
|
|
L. M. Moura, J. L. Zamorano, S. F. Ramos, I. M. Barros, L. F. Azevedo, F. Rocha-Goncalves, and N. M. Rajamannan Reply J. Am. Coll. Cardiol., July 17, 2007; 50(3): 290 - 290. [Full Text] [PDF]
|
|
|
|
|
|
M. B. Yilmaz Statins and Aortic Stenosis in the Context of Ratio of Low- to High-Density Lipoprotein Cholesterol J. Am. Coll. Cardiol., July 17, 2007; 50(3): 289 - 290. [Full Text] [PDF]
|
|
|
|
|
|
B. P. Griffin Statins in Aortic Stenosis: New Data From a Prospective Clinical Trial J. Am. Coll. Cardiol., February 6, 2007; 49(5): 562 - 564. [Full Text] [PDF]
|
|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
